SAHPRA recently announced the registration of two new paediatric formulations for the treatment of HIV. Both will, hopefully, make treating paediatric easier for both our little patients and their carers.

The first is a 10 mg dispersible tablet formulation of dolutegravir (DTG). The second is a novel 4-in-1 formulation of abacavir/lamividune/lopinavir/ritonavir (ABC/3TC/LPVr) that is palatable and can be sprinkled on soft food or dissolved in water or milk.

Find the media release here.